Aβ-immunization reduces learning impairment and amyloid plaque burden in an animal model of Alzheimer's disease

2002 ◽  
Vol 12 ◽  
pp. 98
Author(s):  
D. Westaway ◽  
C. Janus ◽  
H. Johnson ◽  
M.A. Chishti ◽  
J. McLaurin ◽  
...  
2007 ◽  
Vol 28 (8) ◽  
pp. 1206-1214 ◽  
Author(s):  
Sergey Kalinin ◽  
Vitaliy Gavrilyuk ◽  
Paul E. Polak ◽  
Robert Vasser ◽  
Jie Zhao ◽  
...  

2015 ◽  
Vol 24 (1) ◽  
pp. 40-41
Author(s):  
Ayfer Yurt Kılcar ◽  
Zümrüt Fazilet Biber Müftüler ◽  
Vedat Evren ◽  
Ersin Oğuz Koylu ◽  
Lütfiye Kanıt ◽  
...  

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
David J. Braun ◽  
Edgardo Dimayuga ◽  
Josh M. Morganti ◽  
Linda J. Van Eldik

Abstract Background Elevated blood homocysteine levels, termed hyperhomocysteinemia (HHcy), is a prevalent risk factor for Alzheimer’s disease (AD) in elderly populations. While dietary supplementation of B-vitamins is a generally effective method to lower homocysteine levels, there is little if any benefit to cognition. In the context of amyloid pathology, dietary-induced HHcy is known to enhance amyloid deposition and certain inflammatory responses. Little is known, however, about whether there is a more specific effect on microglia resulting from combined amyloid and HHcy pathologies. Methods The present study used a knock-in mouse model of amyloidosis, aged to 12 months, given 8 weeks of B-vitamin deficiency-induced HHcy to better understand how microglia are affected in this comorbidity context. Results We found that HHcy-inducing diet increased amyloid plaque burden, altered the neuroinflammatory milieu, and upregulated the expression of multiple damage-associated and “homeostatic” microglial genes. Conclusions Taken together, these data indicate complex effects of comorbid pathologies on microglial function that are not driven solely by increased amyloid burden. Given the highly dynamic nature of microglia, their central role in AD pathology, and the frequent occurrence of various comorbidities in AD patients, it is increasingly important to understand how microglia respond to mixed pathological processes.


2014 ◽  
Vol 10 ◽  
pp. P410-P411
Author(s):  
Ayfer Yurt KIlçar ◽  
Fazilet Zümrüt Biber Müftüler ◽  
Vedat Evren ◽  
Ersin Oguz Koylu ◽  
Lutfiye Kanit ◽  
...  

2020 ◽  
Vol 21 (9) ◽  
pp. 3270
Author(s):  
Ruth Maron ◽  
Gad Armony ◽  
Michael Tsoory ◽  
Meir Wilchek ◽  
Dan Frenkel ◽  
...  

The two major proteins involved in Alzheimer’s disease (AD) are the amyloid precursor protein (APP) and Tau. Here, we demonstrate that these two proteins can bind to each other. Four possible peptides APP1 (390–412), APP2 (713–730), Tau1 (19–34) and Tau2 (331–348), were predicted to be involved in this interaction, with actual binding confirmed for APP1 and Tau1. In vivo studies were performed in an Alzheimer Disease animal model—APP double transgenic (Tg) 5xFAD—as well as in 5xFAD crossed with Tau transgenic 5xFADXTau (FT), which exhibit declined cognitive reduction at four months of age. Nasal administration of APP1 and Tau1 mixture, three times a week for four or five months, reduced amyloid plaque burden as well as the level of soluble Aβ 1–42 in the brain. The treatment prevented the deterioration of cognitive functions when initiated at the age of three months, before cognitive deficiency was evident, and also at the age of six months, when such deficiencies are already observed, leading to a full regain of cognitive function.


2018 ◽  
Vol 34 (6) ◽  
pp. 912-920 ◽  
Author(s):  
Dongpi Wang ◽  
Xiaoqin Zhang ◽  
Mingkai Wang ◽  
Dongming Zhou ◽  
Hongyu Pan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document